Please assess the completion status of the following clinical trial:

Trial Title: Spironolactone Versus Prednisolone in DMD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Duchenne muscular dystrophy (DMD) patients ≥4 to ≤7 years of age~* Clinical features of DMD that include proximal predominant weakness and/or gait disturbance~* Presence of a truncating mutation of the DMD gene in the patient or an affected male relative OR a muscle biopsy that demonstrates \<5% dystrophin in the patient or an affected male relative~* Normal left ventricular ejection fraction by screening echocardiogram~* Ability to cooperate for testing~* No prior treatment with glucocorticoids or vamorolone~* No concomitant experimental therapies~Exclusion Criteria:~* Subject amenable to or currently being treated with eteplirsen, casimersen, or viltolarsen~* Hyperkalemia at screening~* History of or ongoing renal failure (elevated creatinine, oliguria, anuria)~* Hypersensitivity to spironolactone (rash, respiratory distress, arrhythmia, numbness or tingling of extremities)~* Current treatment with an ACEi~* Severe peptic ulcer disease or recent gastrointestinal perforations

- Gender: MALE
- Minimum Age: 4 Years
- Maximum Age: 7 Years
- Healthy Volunteers: f

Study Arms:
- Spironolactone (Type: EXPERIMENTAL): An anticipated twelve subjects will be prescribed a standard clinical dose of spironolactone of 1 mg/kg/day. The spironolactone will be provided as suspension.
- Prednisolone (Type: ACTIVE_COMPARATOR): An anticipated twelve subjects will be prescribed a standard clinical dose of prednisolone of 0.75 mg/kg/day or weekend dosing per sites standard of care. The prednisolone will be provided will be provided as suspension.

Based on this trial design, predict the completion outcome and termination type (if applicable).